Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph 1/II REGN4018 Adm Alone/ Comb w/Cemiplimab in Pts w/ Platinum-Resistant Ovarian Ca

Protocol: OSU-18027

Full Title

A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer

Gynecologic Cancers Ovarian Cancer